ICYMI – Where’s Robert Stack When You Need Him?

05-5-2015 Blog PostsPress Release

ICYMI May 5, 2015  The New York Times: Runaway Drug Prices How companies set prices of specialty drugs for these and other complex diseases, like cancer and AIDS, has been a mystery to the patients who need them.” “The drug and biotech companies contend that high prices are justified to cover the large costs of bringing […]

ICYMI: High Drug Costs Impact Wall Street and Spark a New Initiative in the White House

04-28-2015 Blog PostsPress Release

April 28, 2015 Note: Distributing the New York Times article below is not an endorsement for President Obama’s proposed initiative.  New York Times: Obama Proposes That Medicare Be Given the Right to Negotiate the Cost of Drugs “Five years after passage of the Affordable Care Act, drug prices are emerging again as a political issue. On a […]

Are Skyrocketing Drug Prices Really Needed for Innovation?

04-22-2015 Blog PostsPress Release

Are Skyrocketing Drug Prices Really Needed for Innovation?   Amgen’s earnings report today indicates that R&D costs fell 14% while drug prices continue to climb.  Enbrel’s price increased 19% while the price of Neulasta continued to climb as well. “The pharmaceutical industry’s argument about needing high prices to fund innovation through R&D fall flat. It’s clear there […]

ICYMI: National Journal article features CSRxP’s White Paper

04-21-2015 Blog PostsPress Release

This morning, the National Journal published an article regarding an increase in public concern over the high cost of prescription drugs. The article references CSRxP’s white paper, “Specialty Drug Hyperinflation: The Risk to Patients and the Health Care System.”

American College of Physicians Joins Campaign for Sustainable Rx Pricing

02-3-2015 Blog PostsPress Release

The American College of Physicians, the largest medical-specialty organization and second-largest physician group in the United States, has joined the Campaign for Sustainable Rx Pricing (CSRxP), a broad-based coalition working for solutions to skyrocketing prescription medicine prices.

I Don’t Want to Say “I Told You So,” But…

11-13-2014 Blog PostsPress Release

The National Association of Medicaid Directors (NAMD) issued a letter to Congress last month that included a variety of interesting proposals but also raised the specter of direct or indirect price controls for the very high-priced Hepatitis drugs that are devastating state Medicaid budgets.

Justifying After the Fact Is Not Justification

10-22-2014 Blog PostsPress Release

What the study should have asked is whether or not the price Gilead set for the therapy is appropriate for all patients–even asymptomatic patients–and whether or not such a large portion of potential societal value should accrue to one company.

Say What? Gilead Exec Compares Rx Spending to McDonald’s Prices

10-15-2014 Blog PostsPress Release

On the day that Gilead introduced its new $94,500 hepatitis C drug, Harvoni, Gilead Vice President of Investor Relations Patrick O’Brien went into full spin mode, telling Politico (subscription required) that Harvoni is a bargain compared to Gilead’s other hep C drug, the $84,000 Sovaldi.

Gilead–The Predictable Path or the Road Less Traveled?

09-17-2014 Blog PostsPress Release

Gilead should be commended for taking action to make their best-selling treatment for Hepatitis C, Sovaldi, available to more people around the world. In India, they’ve struck licensing agreements with generic firms to produce the product for pennies on the dollar. Unfortunately, Gilead’s largess is being funded largely on the backs of American families.

Gilead Can Afford to Take These Three Steps to Lower the Price of Sovaldi

07-24-2014 Blog PostsPress Release

Yesterday’s blockbuster earnings announcement from Gilead underscores how much room the drug manufacturer has to lower the price of its Hepatitis C drug Sovaldi.  In fact, nearly all of Gilead’s profits came from its U.S. sales of Sovaldi. The $3.48 billion that Gilead earned from sales of Sovaldi in the second quarter is only going […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.